



U.S. CONSUMER PRODUCT SAFETY COMMISSION  
4330 EAST WEST HIGHWAY  
BETHESDA, MARYLAND 20814-4408

Record of Commission Action  
Commissioners Voting by Ballot\*

Commissioners Voting:      Acting Chairman Robert S. Adler  
   Commissioner Dana Baiocco  
   Commissioner Peter A. Feldman

ITEM:

Petition to Exempt Baloxavir Marboxil (XOFLUZA™) in 40 mg and 80 mg Tablet Doses from Special Packaging Requirements of the Poison Prevention Packaging Act (Briefing package dated September 1, 2021, OS No. 0075)

DECISION:

The Commission voted unanimously (3-0) to grant Petition PP 20-1, requesting exemption for baloxavir marboxil, (XOFLUZA™) in 40 mg or 80 mg tablet doses from special packaging requirements under the Poison Prevention Packaging Act (PPPA), and direct staff to publish a notice of proposed rulemaking in the *Federal Register*. The petition was submitted by Genentech, Inc.

For the Commission:

Alberta Mills  
Secretary

\* Ballot vote due September 8, 2021